Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Market Cap
$1.37B
P/E Ratio
-11.54
1Y Stock Return
-14.19%
1Y Revenue Growth
12.15%
Dividend Yield
0.00%
Price to Book
1.9
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Yahoo
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor typesSALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies. Myriad’s gold-standard Genomic Instability Score (GIS) to determine Homologous Re
Yahoo
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that the Prequel® Prenatal Screen is now available at eight weeks into pregnancy. Enabled by its AMPLIFY™ technology, Prequel is the first and only prenatal cell-free DNA (cfDNA) screen available at eight-weeks gestational age. “Previously, I would schedule my patients to come in at eight weeks for their first prenatal appointment; then, I would as
Yahoo
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $21 from $32 and keeps an Equal Weight rating on the shares. Q3 results came in slightly above the preliminary view as average selling price strength more than offset some volume softness, the analyst noted. UnitedHealth’s (UNH) decision to drop coverage of multi-gene behavioral health PGx tests equates annually to about $40M in revenue and about $30M in gross profit impact, notes the analyst, who adds that “broader payo
Finnhub
Statement regarding use of non-GAAP financial measures In this press release, the company's financial results and financial guidance are provided in accordance with accounting...
Finnhub
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. . Investors who purchased Myriad securities are encouraged...
Yahoo
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LPX | 48.89% | $7.84B | +85.45% | 0.70% |
HY | 47.72% | $948.82M | +15.25% | 2.47% |
HASI | 47.61% | $3.29B | +16.65% | 5.90% |
DNLI | 47.55% | $3.50B | +33.66% | 0.00% |
ELAN | 45.86% | $6.58B | +12.99% | 0.00% |
CRCT | 45.57% | $1.12B | -19.90% | 1.91% |
GMED | 42.89% | $11.35B | +81.49% | 0.00% |
GMRE | 42.65% | $579.18M | -10.99% | 9.69% |
AMRC | 40.31% | $1.39B | -4.40% | 0.00% |
KFRC | 40.04% | $1.10B | -8.71% | 0.66% |
SBCF | 39.62% | $2.50B | +28.16% | 2.45% |
MFA | 39.32% | $1.13B | +5.15% | 12.73% |
KMT | 37.98% | $2.17B | +21.08% | 2.88% |
VTOL | 37.90% | $1.07B | +42.07% | 0.00% |
KD | 37.69% | $6.51B | +55.09% | 0.00% |
SCSC | 37.64% | $1.17B | +54.80% | 0.00% |
PLAB | 37.56% | $1.52B | +12.34% | 0.00% |
GT | 37.52% | $2.60B | -34.81% | 0.00% |
OFIX | 37.47% | $715.75M | +67.38% | 0.00% |
FLGT | 37.45% | $519.98M | -37.82% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYCN | 0.02% | $4.77M | -16.19% | 0.00% |
SMMT | 0.05% | $14.74B | +910.10% | 0.00% |
SRPT | -0.06% | $10.18B | +26.81% | 0.00% |
NTIC | -0.10% | $132.27M | +24.98% | 2.02% |
GOGL | 0.12% | $2.39B | +35.11% | 8.40% |
RGR | 0.13% | $642.75M | -15.87% | 1.81% |
RAMP | 0.16% | $1.86B | -16.17% | 0.00% |
ACRS | 0.18% | $327.87M | +415.67% | 0.00% |
CCEC | -0.19% | $1.02B | +28.03% | 3.26% |
NHTC | -0.21% | $61.83M | +0.19% | 14.81% |
SMLR | -0.27% | $336.72M | +25.48% | 0.00% |
IRWD | 0.34% | $609.71M | -59.34% | 0.00% |
BYND | 0.38% | $318.19M | -22.91% | 0.00% |
RLMD | 0.38% | $89.92M | +1.36% | 0.00% |
IMRN | -0.39% | $10.31M | -5.04% | 0.00% |
PG | 0.43% | $402.15B | +14.14% | 2.33% |
UTZ | 0.43% | $1.37B | +26.87% | 1.41% |
AVDL | -0.44% | $1.03B | -3.16% | 0.00% |
TRVG | 0.49% | $37.05M | -37.92% | 0.00% |
CTMX | -0.52% | $69.86M | -31.59% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MCK | -22.00% | $78.15B | +35.51% | 0.42% |
CAH | -20.78% | $28.64B | +12.14% | 1.70% |
GO | -20.40% | $1.81B | -34.42% | 0.00% |
TRIP | -18.43% | $1.87B | -29.46% | 0.00% |
COR | -15.67% | $47.48B | +21.20% | 0.86% |
TMCI | -14.26% | $483.43M | -8.71% | 0.00% |
BTCT | -13.41% | $42.61M | +353.33% | 0.00% |
DV | -13.37% | $3.26B | -37.48% | 0.00% |
MNOV | -9.79% | $93.19M | +2.15% | 0.00% |
MNR | -9.56% | $1.66B | -10.71% | 15.90% |
NOC | -9.10% | $71.54B | +4.23% | 1.60% |
PRPO | -7.66% | $9.10M | -13.65% | 0.00% |
NTZ | -7.55% | $47.64M | -30.94% | 0.00% |
LMT | -7.17% | $126.40B | +18.99% | 2.36% |
MCS | -6.52% | $669.85M | +49.35% | 1.28% |
HUSA | -6.20% | $16.69M | -11.56% | 0.00% |
ZI | -5.75% | $3.40B | -28.47% | 0.00% |
TILE | -5.43% | $1.45B | +150.00% | 0.16% |
CSTE | -5.36% | $134.01M | +2.92% | 0.00% |
ODP | -5.16% | $777.35M | -46.62% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SGOV | -0.05% | $27.53B | 0.09% |
ICLO | 0.28% | $209.30M | 0.2% |
SOYB | 0.42% | $27.32M | 0.22% |
HIGH | 0.50% | $302.78M | 0.51% |
GBIL | -0.63% | $5.60B | 0.12% |
CSHI | 0.64% | $482.85M | 0.38% |
KRBN | -1.07% | $242.47M | 0.85% |
UNG | 1.07% | $908.80M | 1.06% |
HDRO | -1.34% | $164.26M | 0.3% |
KCCA | -1.36% | $220.51M | 0.87% |
TBIL | -1.72% | $4.38B | 0.15% |
FLRN | 1.87% | $2.33B | 0.15% |
JUCY | 2.07% | $324.29M | 0.6% |
BSCO | 2.32% | $2.35B | 0.1% |
BOXX | -2.40% | $4.43B | 0.1949% |
IBTE | 2.69% | $1.70B | 0.07% |
DBMF | 4.02% | $1.02B | 0.85% |
SHV | 4.08% | $18.13B | 0.15% |
DBO | 4.09% | $217.57M | 0.77% |
XBIL | 4.19% | $637.70M | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -32.32% | $388.04M | 1.43% |
VIXY | -23.23% | $195.31M | 0.85% |
USDU | -21.66% | $201.97M | 0.5% |
UUP | -19.94% | $309.25M | 0.77% |
CTA | -17.25% | $350.27M | 0.78% |
CORN | -13.98% | $61.12M | 0.2% |
WEAT | -13.78% | $120.27M | 0.28% |
EQLS | -11.58% | $76.08M | 1% |
KMLM | -10.42% | $353.87M | 0.9% |
AGZD | -9.97% | $142.76M | 0.23% |
TAIL | -9.74% | $67.98M | 0.59% |
CCOR | -7.79% | $109.04M | 1.18% |
CLOI | -6.28% | $715.40M | 0.4% |
JBBB | -5.08% | $1.26B | 0.49% |
MINT | -4.79% | $11.62B | 0.35% |
BILZ | -4.47% | $563.02M | 0.14% |
BOXX | -2.40% | $4.43B | 0.1949% |
TBIL | -1.72% | $4.38B | 0.15% |
KCCA | -1.36% | $220.51M | 0.87% |
HDRO | -1.34% | $164.26M | 0.3% |
Current Value
$14.931 Year Return
Current Value
$14.931 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 47.50% | $6.66B | 0.45% |
GNOM | 46.64% | $70.59M | 0.5% |
ARKX | 45.35% | $249.95M | 0.75% |
IWO | 45.13% | $12.56B | 0.24% |
QQQJ | 45.06% | $698.04M | 0.15% |
MOAT | 44.97% | $15.73B | 0.46% |
IVOV | 44.78% | $964.95M | 0.15% |
FYX | 44.78% | $959.00M | 0.6% |
SMLF | 44.38% | $1.44B | 0.15% |
MORT | 43.47% | $293.96M | 0.43% |
CGW | 42.50% | $962.52M | 0.56% |
NUSC | 41.80% | $1.27B | 0.31% |
PRFZ | 41.66% | $2.65B | 0.39% |
IWN | 41.50% | $13.17B | 0.24% |
VBR | 41.44% | $32.03B | 0.07% |
IWS | 41.37% | $13.85B | 0.23% |
REM | 41.36% | $632.41M | 0.48% |
DON | 41.24% | $3.90B | 0.38% |
JVAL | 41.23% | $693.47M | 0.12% |
IJS | 41.23% | $7.37B | 0.18% |